25 XP   0   0   10

NextCure  Inc
Buy, Hold or Sell?

Let's analyse Nextcure together

PenkeI guess you are interested in NextCure  Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NextCure  Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NextCure  Inc

I send you an email if I find something interesting about NextCure  Inc.

Quick analysis of Nextcure (30 sec.)










What can you expect buying and holding a share of Nextcure? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.10
Expected worth in 1 year
$2.20
How sure are you?
14.3%

+ What do you gain per year?

Total Gains per Share
$-1.90
Return On Investment
-119.0%

For what price can you sell your share?

Current Price per Share
$1.60
Expected price per share
$1.15 - $2.66
How sure are you?
50%

1. Valuation of Nextcure (5 min.)




Live pricePrice per Share (EOD)

$1.60

Intrinsic Value Per Share

$-20.94 - $-24.34

Total Value Per Share

$-16.84 - $-20.24

2. Growth of Nextcure (5 min.)




Is Nextcure growing?

Current yearPrevious yearGrowGrow %
How rich?$114.4m$190.3m-$56.9m-42.7%

How much money is Nextcure making?

Current yearPrevious yearGrowGrow %
Making money-$15.4m-$18.3m$2.9m19.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Nextcure (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#353 / 1016

Most Revenue
#728 / 1016

Most Profit
#638 / 1016

Most Efficient
#165 / 1016

What can you expect buying and holding a share of Nextcure? (5 min.)

Welcome investor! Nextcure's management wants to use your money to grow the business. In return you get a share of Nextcure.

What can you expect buying and holding a share of Nextcure?

First you should know what it really means to hold a share of Nextcure. And how you can make/lose money.

Speculation

The Price per Share of Nextcure is $1.6. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nextcure.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nextcure, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.10. Based on the TTM, the Book Value Change Per Share is $-0.48 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nextcure.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.52-32.4%-0.56-35.1%-0.67-41.8%-0.50-31.1%-0.49-30.3%
Usd Book Value Change Per Share-0.43-27.0%-0.48-29.8%-0.59-36.9%0.2918.1%0.2012.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-27.0%-0.48-29.8%-0.59-36.9%0.2918.1%0.2012.2%
Usd Price Per Share1.14-1.43-3.43-11.53-10.98-
Price to Earnings Ratio-0.55--0.63--1.26--4.26--4.06-
Price-to-Total Gains Ratio-2.64--2.98--5.68--16.08--16.08-
Price to Book Ratio0.28-0.30-0.49-1.29-1.22-
Price-to-Total Gains Ratio-2.64--2.98--5.68--16.08--16.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.6
Number of shares625
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.480.29
Usd Total Gains Per Share-0.480.29
Gains per Quarter (625 shares)-297.56180.69
Gains per Year (625 shares)-1,190.23722.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1190-12000723713
20-2380-2390014461436
30-3571-3580021682159
40-4761-4770028912882
50-5951-5960036143605
60-7141-7150043374328
70-8332-8340050595051
80-9522-9530057825774
90-10712-10720065056497
100-11902-11910072287220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.020.00.04.8%1.020.00.04.8%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%3.018.00.014.3%3.018.00.014.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%3.018.00.014.3%3.018.00.014.3%

Fundamentals of Nextcure

About NextCure  Inc

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Fundamental data was last updated by Penke on 2024-04-11 16:29:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NextCure  Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nextcure earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nextcure to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NextCure  Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-103.7%+103.7%
5Y-103.7%10Y-98.8%-4.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y-103.7%-438.4%+334.7%
10Y-98.8%-605.5%+506.7%
1.1.2. Return on Assets

Shows how efficient Nextcure is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nextcure to the Biotechnology industry mean.
  • -11.2% Return on Assets means that Nextcure generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NextCure  Inc:

  • The MRQ is -11.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.2%TTM-10.5%-0.7%
TTM-10.5%YOY-9.2%-1.3%
TTM-10.5%5Y-6.6%-3.9%
5Y-6.6%10Y-6.5%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.2%-13.5%+2.3%
TTM-10.5%-12.9%+2.4%
YOY-9.2%-11.8%+2.6%
5Y-6.6%-14.1%+7.5%
10Y-6.5%-16.0%+9.5%
1.1.3. Return on Equity

Shows how efficient Nextcure is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nextcure to the Biotechnology industry mean.
  • -12.6% Return on Equity means Nextcure generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NextCure  Inc:

  • The MRQ is -12.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.6%TTM-11.7%-1.0%
TTM-11.7%YOY-9.7%-2.0%
TTM-11.7%5Y-6.9%-4.8%
5Y-6.9%10Y-6.6%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.6%-16.9%+4.3%
TTM-11.7%-16.1%+4.4%
YOY-9.7%-15.1%+5.4%
5Y-6.9%-19.9%+13.0%
10Y-6.6%-20.9%+14.3%

1.2. Operating Efficiency of NextCure  Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nextcure is operating .

  • Measures how much profit Nextcure makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nextcure to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NextCure  Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-115.8%+115.8%
5Y-115.8%10Y-110.3%-5.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y-115.8%-477.4%+361.6%
10Y-110.3%-625.6%+515.3%
1.2.2. Operating Ratio

Measures how efficient Nextcure is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NextCure  Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.978-1.978
5Y1.97810Y1.883+0.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y1.9785.679-3.701
10Y1.8837.894-6.011

1.3. Liquidity of NextCure  Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nextcure is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 16.38 means the company has $16.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NextCure  Inc:

  • The MRQ is 16.377. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.042. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ16.377TTM19.042-2.665
TTM19.042YOY28.530-9.488
TTM19.0425Y27.303-8.261
5Y27.30310Y26.631+0.672
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.3773.914+12.463
TTM19.0424.220+14.822
YOY28.5305.388+23.142
5Y27.3036.045+21.258
10Y26.6316.406+20.225
1.3.2. Quick Ratio

Measures if Nextcure is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nextcure to the Biotechnology industry mean.
  • A Quick Ratio of 29.68 means the company can pay off $29.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NextCure  Inc:

  • The MRQ is 29.684. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 33.759. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ29.684TTM33.759-4.075
TTM33.759YOY51.394-17.635
TTM33.7595Y48.728-14.969
5Y48.72810Y47.032+1.695
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.6843.572+26.112
TTM33.7593.998+29.761
YOY51.3945.390+46.004
5Y48.7285.969+42.759
10Y47.0326.287+40.745

1.4. Solvency of NextCure  Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nextcure assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nextcure to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Nextcure assets are financed with 11.6% credit (debt) and the remaining percentage (100% - 11.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NextCure  Inc:

  • The MRQ is 0.116. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.098. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.098+0.018
TTM0.098YOY0.053+0.044
TTM0.0985Y0.135-0.037
5Y0.13510Y0.191-0.056
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1160.336-0.220
TTM0.0980.334-0.236
YOY0.0530.269-0.216
5Y0.1350.366-0.231
10Y0.1910.390-0.199
1.4.2. Debt to Equity Ratio

Measures if Nextcure is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nextcure to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.1% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NextCure  Inc:

  • The MRQ is 0.131. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.108. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.131TTM0.108+0.023
TTM0.108YOY0.057+0.052
TTM0.1085Y0.074+0.035
5Y0.07410Y0.070+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1310.382-0.251
TTM0.1080.396-0.288
YOY0.0570.335-0.278
5Y0.0740.434-0.360
10Y0.0700.465-0.395

2. Market Valuation of NextCure  Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nextcure generates.

  • Above 15 is considered overpriced but always compare Nextcure to the Biotechnology industry mean.
  • A PE ratio of -0.55 means the investor is paying $-0.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NextCure  Inc:

  • The EOD is -0.772. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.550. Based on the earnings, the company is expensive. -2
  • The TTM is -0.631. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.772MRQ-0.550-0.222
MRQ-0.550TTM-0.631+0.081
TTM-0.631YOY-1.265+0.634
TTM-0.6315Y-4.262+3.631
5Y-4.26210Y-4.059-0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.772-2.259+1.487
MRQ-0.550-2.569+2.019
TTM-0.631-2.664+2.033
YOY-1.265-4.120+2.855
5Y-4.262-6.258+1.996
10Y-4.059-6.171+2.112
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NextCure  Inc:

  • The EOD is -1.045. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.745. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.739. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.045MRQ-0.745-0.300
MRQ-0.745TTM-0.739-0.005
TTM-0.739YOY-1.647+0.908
TTM-0.7395Y-7.058+6.319
5Y-7.05810Y-6.722-0.336
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.045-2.924+1.879
MRQ-0.745-3.246+2.501
TTM-0.739-3.488+2.749
YOY-1.647-5.620+3.973
5Y-7.058-8.315+1.257
10Y-6.722-8.826+2.104
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nextcure is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.28 means the investor is paying $0.28 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NextCure  Inc:

  • The EOD is 0.390. Based on the equity, the company is cheap. +2
  • The MRQ is 0.278. Based on the equity, the company is cheap. +2
  • The TTM is 0.298. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.390MRQ0.278+0.112
MRQ0.278TTM0.298-0.020
TTM0.298YOY0.488-0.190
TTM0.2985Y1.286-0.988
5Y1.28610Y1.225+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3901.851-1.461
MRQ0.2782.090-1.812
TTM0.2982.095-1.797
YOY0.4882.844-2.356
5Y1.2863.466-2.180
10Y1.2253.815-2.590
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NextCure  Inc.

3.1. Institutions holding NextCure  Inc

Institutions are holding 43.134% of the shares of NextCure  Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Orbimed Advisors, LLC9.71580.0617271101300
2023-12-31Sofinnova Ventures9.57550.1704267185600
2023-12-31Millennium Management LLC4.0870.00061140389-282165-19.8351
2023-12-31Vanguard Group Inc3.238409036241970.0218
2023-12-31BlackRock Inc3.190890102-8004-0.8912
2023-12-31Cable Car Capital LLC2.20720.7296158786158780
2023-12-31Long Focus Capital Management, LLC1.9930.021155610500
2023-12-31Acadian Asset Management LLC1.75050.002248844000
2023-09-30Citadel Advisors Llc1.57190.00014386104534711.531
2023-09-30TANG CAPITAL MANAGEMENT LLC1.43350.072840000000
2023-12-31Acuitas Investments, LLC1.33610.25673727998598229.978
2023-12-31Federated Hermes Inc1.1750.0009327847-38979-10.626
2023-12-31BML Capital Management LLC1.09830.264630646500
2023-12-31Renaissance Technologies Corp1.05120.00052933154311517.2322
2023-12-31Geode Capital Management, LLC0.6261017470700
2023-12-31Macquarie Group Ltd0.53760.000215000000
2023-12-31Sio Capital Management, LLC0.46590.033713000000
2023-12-31Bridgeway Capital Management, LLC0.3390.00239460000
2023-12-31Dimensional Fund Advisors, Inc.0.3077085853-9867-10.3082
2023-12-31Morgan Stanley - Brokerage Accounts0.2897080828808278082700
Total 45.98941.616812832431+532331+4.1%

3.2. Funds holding NextCure  Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.19990.000161382700
2023-12-31Federated Hermes MDT Small Cap Growth IS1.12960.0772315180-38395-10.8591
2023-12-31Federated Hermes MDT SCG Institutional1.12960.0769315180-38395-10.8591
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.72390.000320197800
2023-12-31Vanguard Explorer Inv0.61470.000917151900
2024-02-29BlackRock Advantage Small Cap Core Instl0.60850.008416978900
2024-01-31Delaware Healthcare I0.53760.024915000000
2023-12-31LUNIS Biotech Growth Opp Fd I a0.34083.79719510300
2024-01-31Fidelity Extended Market Index0.33920.00039465900
2023-12-31Bridgeway Ultra-Small Company Market0.32220.05528990000
2024-02-29iShares Micro-Cap ETF0.18140.00965060600
2023-09-30BlackRock Extended Mkt Composite0.10730.00032993100
2024-01-31Fidelity Total Market Index0.103902899500
2023-12-31BlackRock Extended Equity Market K0.09360.000226112-53-0.2026
2024-01-31Fidelity Series Total Market Index0.08750.00012441100
2023-12-31Franklin U.S. Small Cap Equity I0.06560.0221831100
2024-01-31Fidelity Nasdaq Composite Index0.05430.00011514000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05220.00031455800
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04770.00031330200
2023-12-31Northern Trust Extended Eq Market Idx0.04770.00031330200
Total 8.78724.07452451803-76843-3.1%

3.3. Insider Transactions

Insiders are holding 8.84% of the shares of NextCure  Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2019-11-15Sofinnova Venture Partners Ix,BUY15000036.75
2019-05-13Stella XuBUY12500015
2019-05-13X L.p. CanaanBUY5000015

4. Summary

4.1. Key Performance Indicators

The key performance indicators of NextCure  Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.432-0.476+10%-0.590+37%0.289-249%0.195-321%
Book Value Per Share--4.1004.780-14%6.820-40%7.482-45%7.046-42%
Current Ratio--16.37719.042-14%28.530-43%27.303-40%26.631-39%
Debt To Asset Ratio--0.1160.098+19%0.053+117%0.135-14%0.191-39%
Debt To Equity Ratio--0.1310.108+21%0.057+130%0.074+78%0.070+87%
Dividend Per Share----0%-0%-0%-0%
Eps---0.518-0.562+8%-0.670+29%-0.498-4%-0.486-6%
Free Cash Flow Per Share---0.383-0.482+26%-0.502+31%-0.466+22%-0.408+7%
Free Cash Flow To Equity Per Share---0.380-0.480+26%-0.499+31%-0.038-90%0.154-347%
Gross Profit Margin--1.0571.014+4%1.000+6%1.003+5%1.003+5%
Intrinsic Value_10Y_max---24.338--------
Intrinsic Value_10Y_min---20.937--------
Intrinsic Value_1Y_max---2.087--------
Intrinsic Value_1Y_min---2.049--------
Intrinsic Value_3Y_max---6.538--------
Intrinsic Value_3Y_min---6.236--------
Intrinsic Value_5Y_max---11.313--------
Intrinsic Value_5Y_min---10.477--------
Market Cap44644800.000+29%31817377.20039833521.800-20%95707290.000-67%324373532.263-90%308927173.583-90%
Net Profit Margin----0%-0%-1.0370%-0.9880%
Operating Margin----0%-0%-1.1580%-1.1030%
Operating Ratio----0%-0%1.978-100%1.883-100%
Pb Ratio0.390+29%0.2780.298-7%0.488-43%1.286-78%1.225-77%
Pe Ratio-0.772-40%-0.550-0.631+15%-1.265+130%-4.262+675%-4.059+638%
Price Per Share1.600+29%1.1401.428-20%3.430-67%11.529-90%10.980-90%
Price To Free Cash Flow Ratio-1.045-40%-0.745-0.739-1%-1.647+121%-7.058+848%-6.722+803%
Price To Total Gains Ratio-3.702-40%-2.638-2.981+13%-5.680+115%-16.077+510%-16.077+510%
Quick Ratio--29.68433.759-12%51.394-42%48.728-39%47.032-37%
Return On Assets---0.112-0.105-6%-0.092-18%-0.066-41%-0.065-42%
Return On Equity---0.126-0.117-8%-0.097-23%-0.069-46%-0.066-48%
Total Gains Per Share---0.432-0.476+10%-0.590+37%0.289-249%0.195-321%
Usd Book Value--114421000.000133376500.000-14%190300750.000-40%209591400.000-45%197375428.571-42%
Usd Book Value Change Per Share---0.432-0.476+10%-0.590+37%0.289-249%0.195-321%
Usd Book Value Per Share--4.1004.780-14%6.820-40%7.482-45%7.046-42%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.518-0.562+8%-0.670+29%-0.498-4%-0.486-6%
Usd Free Cash Flow---10683000.000-13448500.000+26%-14000500.000+31%-13024000.000+22%-11424428.571+7%
Usd Free Cash Flow Per Share---0.383-0.482+26%-0.502+31%-0.466+22%-0.408+7%
Usd Free Cash Flow To Equity Per Share---0.380-0.480+26%-0.499+31%-0.038-90%0.154-347%
Usd Market Cap44644800.000+29%31817377.20039833521.800-20%95707290.000-67%324373532.263-90%308927173.583-90%
Usd Price Per Share1.600+29%1.1401.428-20%3.430-67%11.529-90%10.980-90%
Usd Profit---14467000.000-15437000.000+7%-18389500.000+27%-13751750.000-5%-13423666.667-7%
Usd Revenue----0%-0%1436250.000-100%1367857.143-100%
Usd Total Gains Per Share---0.432-0.476+10%-0.590+37%0.289-249%0.195-321%
 EOD+5 -3MRQTTM+17 -13YOY+16 -145Y+9 -2310Y+9 -23

4.2. Fundamental Score

Let's check the fundamental score of NextCure  Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.772
Price to Book Ratio (EOD)Between0-10.390
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than129.684
Current Ratio (MRQ)Greater than116.377
Debt to Asset Ratio (MRQ)Less than10.116
Debt to Equity Ratio (MRQ)Less than10.131
Return on Equity (MRQ)Greater than0.15-0.126
Return on Assets (MRQ)Greater than0.05-0.112
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of NextCure  Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.574
Ma 20Greater thanMa 501.959
Ma 50Greater thanMa 1001.711
Ma 100Greater thanMa 2001.456
OpenGreater thanClose1.580
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets129,418
Total Liabilities14,997
Total Stockholder Equity114,421
 As reported
Total Liabilities 14,997
Total Stockholder Equity+ 114,421
Total Assets = 129,418

Assets

Total Assets129,418
Total Current Assets112,725
Long-term Assets16,693
Total Current Assets
Cash And Cash Equivalents 13,082
Short-term Investments 95,217
Net Receivables 800
Other Current Assets 3,626
Total Current Assets  (as reported)112,725
Total Current Assets  (calculated)112,725
+/-0
Long-term Assets
Property Plant Equipment 13,431
Long-term Assets Other 1,882
Long-term Assets  (as reported)16,693
Long-term Assets  (calculated)15,313
+/- 1,380

Liabilities & Shareholders' Equity

Total Current Liabilities6,883
Long-term Liabilities8,114
Total Stockholder Equity114,421
Total Current Liabilities
Short-term Debt 656
Accounts payable 2,330
Other Current Liabilities 3,897
Total Current Liabilities  (as reported)6,883
Total Current Liabilities  (calculated)6,883
+/-0
Long-term Liabilities
Capital Lease Obligations 6,605
Long-term Liabilities Other 785
Long-term Liabilities  (as reported)8,114
Long-term Liabilities  (calculated)7,390
+/- 724
Total Stockholder Equity
Common Stock28
Retained Earnings -324,482
Accumulated Other Comprehensive Income -222
Other Stockholders Equity 439,097
Total Stockholder Equity (as reported)114,421
Total Stockholder Equity (calculated)114,421
+/-0
Other
Capital Stock28
Cash and Short Term Investments 108,299
Common Stock Shares Outstanding 27,910
Liabilities and Stockholders Equity 129,418
Net Debt -6,477
Net Invested Capital 114,421
Net Working Capital 105,842
Property Plant and Equipment Gross 33,660
Short Long Term Debt Total 6,605



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
147,628
145,426
213,050
205,124
356,168
343,472
333,489
316,078
306,644
290,959
275,359
257,825
242,386
222,746
206,370
189,909
184,161
167,791
153,380
139,939
129,418
129,418139,939153,380167,791184,161189,909206,370222,746242,386257,825275,359290,959306,644316,078333,489343,472356,168205,124213,050145,426147,628000
   > Total Current Assets 
0
0
0
135,785
131,637
196,521
189,148
339,995
326,664
315,070
296,981
287,978
273,051
258,632
243,036
227,817
208,933
192,954
175,315
163,983
148,918
135,299
122,684
112,725
112,725122,684135,299148,918163,983175,315192,954208,933227,817243,036258,632273,051287,978296,981315,070326,664339,995189,148196,521131,637135,785000
       Cash And Cash Equivalents 
0
0
0
135,173
125,549
192,689
9,935
34,091
28,907
25,050
22,534
32,772
36,527
34,903
36,664
12,337
10,652
28,163
31,050
26,630
29,973
22,019
19,519
13,082
13,08219,51922,01929,97326,63031,05028,16310,65212,33736,66434,90336,52732,77222,53425,05028,90734,0919,935192,689125,549135,173000
       Short-term Investments 
0
0
0
0
0
0
174,147
300,514
293,191
284,285
268,672
250,676
231,709
214,617
198,672
207,254
190,672
157,329
138,164
133,281
115,520
108,604
98,687
95,217
95,21798,687108,604115,520133,281138,164157,329190,672207,254198,672214,617231,709250,676268,672284,285293,191300,514174,147000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
700
0
0
0
800
8000007000000000000000000000
       Other Current Assets 
0
0
0
152
1,049
2,959
3,777
3,684
2,860
4,029
4,069
2,824
3,109
7,406
7,661
8,187
7,609
7,462
6,101
4,072
3,425
4,676
4,478
3,626
3,6264,4784,6763,4254,0726,1017,4627,6098,1877,6617,4063,1092,8244,0694,0292,8603,6843,7772,9591,049152000
   > Long-term Assets 
0
0
0
11,843
13,789
16,529
15,976
16,173
16,808
18,419
19,097
18,666
17,908
16,727
14,789
14,569
13,813
13,416
14,594
20,178
18,873
18,081
17,255
16,693
16,69317,25518,08118,87320,17814,59413,41613,81314,56914,78916,72717,90818,66619,09718,41916,80816,17315,97616,52913,78911,843000
       Property Plant Equipment 
0
0
0
11,407
11,779
12,329
12,031
12,090
12,784
14,831
15,819
15,809
15,470
14,709
14,208
13,992
13,239
12,615
12,125
16,913
16,050
15,223
14,401
13,431
13,43114,40115,22316,05016,91312,12512,61513,23913,99214,20814,70915,47015,80915,81914,83112,78412,09012,03112,32911,77911,407000
       Other Assets 
0
0
0
0
2,010
4,200
3,945
4,083
4,024
3,588
3,278
2,857
2,438
2,018
581
577
574
801
2,469
3,265
0
2,858
0
0
002,85803,2652,4698015745775812,0182,4382,8573,2783,5884,0244,0833,9454,2002,0100000
> Total Liabilities 
0
0
0
194,572
198,138
34,455
34,475
34,684
11,715
11,572
8,739
12,923
11,800
11,761
9,599
9,000
8,810
8,174
8,368
16,631
13,588
14,950
13,487
14,997
14,99713,48714,95013,58816,6318,3688,1748,8109,0009,59911,76111,80012,9238,73911,57211,71534,68434,47534,455198,138194,572000
   > Total Current Liabilities 
0
0
0
10,298
10,305
11,524
12,607
15,042
8,152
8,362
5,741
10,325
8,188
8,565
7,376
6,608
6,424
5,697
5,891
9,127
6,266
7,820
6,552
6,883
6,8836,5527,8206,2669,1275,8915,6976,4246,6087,3768,5658,18810,3255,7418,3628,15215,04212,60711,52410,30510,298000
       Short-term Debt 
0
0
0
514
278
833
1,250
1,802
1,667
1,667
1,667
1,667
1,667
1,667
0
0
0
0
0
518
787
536
276
656
656276536787518000001,6671,6671,6671,6671,6671,6671,8021,250833278514000
       Short Long Term Debt 
0
0
0
0
278
833
1,250
1,667
1,667
1,667
1,667
1,667
1,667
1,667
0
0
0
0
0
0
0
0
0
0
00000000001,6671,6671,6671,6671,6671,6671,6671,2508332780000
       Accounts payable 
0
0
0
2,483
2,938
1,990
2,576
1,861
2,263
2,435
186
3,901
2,017
1,351
2,946
1,942
2,801
2,272
1,846
4,270
1,919
2,813
2,602
2,330
2,3302,6022,8131,9194,2701,8462,2722,8011,9422,9461,3512,0173,9011862,4352,2631,8612,5761,9902,9382,483000
       Other Current Liabilities 
0
0
0
2,312
1,849
2,177
2,582
4,951
4,222
4,260
3,888
-1,671
4,504
5,547
4,430
4,666
3,623
3,425
4,045
4,339
4,347
5,007
3,950
3,897
3,8973,9505,0074,3474,3394,0453,4253,6234,6664,4305,5474,504-1,6713,8884,2604,2224,9512,5822,1771,8492,312000
   > Long-term Liabilities 
0
0
0
184,274
187,833
22,931
21,868
19,642
3,563
3,210
2,998
2,598
3,612
3,196
2,223
2,392
2,386
2,477
2,477
7,504
7,322
7,130
6,935
8,114
8,1146,9357,1307,3227,5042,4772,4772,3862,3922,2233,1963,6122,5982,9983,2103,56319,64221,86822,931187,833184,274000
       Long term Debt Total 
0
0
0
0
4,722
4,167
3,750
3,333
3,056
0
0
1,806
1,389
972
0
0
0
0
0
0
0
0
0
0
00000000009721,3891,806003,0563,3333,7504,1674,7220000
       Other Liabilities 
0
0
0
0
20,888
18,764
18,118
16,309
507
571
776
792
2,223
2,224
2,223
2,392
2,386
2,477
2,477
899
0
843
0
0
0084308992,4772,4772,3862,3922,2232,2242,22379277657150716,30918,11818,76420,8880000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
792
2,223
2,224
2,223
2,392
2,386
2,477
2,477
0
0
0
0
0
000002,4772,4772,3862,3922,2232,2242,22379200000000000
> Total Stockholder Equity
-24,412
0
0
-46,944
-52,712
178,595
170,649
321,484
331,757
321,917
307,339
293,721
279,159
263,598
248,226
233,386
213,936
198,196
181,541
167,530
154,203
138,430
126,452
114,421
114,421126,452138,430154,203167,530181,541198,196213,936233,386248,226263,598279,159293,721307,339321,917331,757321,484170,649178,595-52,712-46,94400-24,412
   Common Stock
0
0
0
11
11
23
23
27
28
28
28
28
28
28
28
28
28
28
28
28
28
28
28
28
282828282828282828282828282828282723231111000
   Retained Earnings Total Equity00-295,714-277,855-261,759-244,459-225,548-207,628-187,026-170,087-152,157-134,170-117,63700000000000
   Accumulated Other Comprehensive Income 
0
0
0
-2,469
-3,032
-3,614
-58
-38
-543
1,935
1,298
779
179
-195
-129
-663
-2,199
-2,340
-2,396
-1,494
-803
-925
-603
-222
-222-603-925-803-1,494-2,396-2,340-2,199-663-129-1951797791,2981,935-543-38-58-3,614-3,032-2,469000
   Capital Surplus 
0
0
0
0
729
240,245
240,791
402,529
403,573
0
0
410,551
413,122
415,922
418,414
421,047
423,735
426,056
428,368
430,755
432,833
435,041
0
0
00435,041432,833430,755428,368426,056423,735421,047418,414415,922413,122410,55100403,573402,529240,791240,2457290000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
2,811
-67,239
30,809
35,667
407,637
60,101
72,274
92,111
410,551
413,122
415,922
418,414
421,047
423,735
426,056
428,368
430,755
432,833
435,041
437,042
439,097
439,097437,042435,041432,833430,755428,368426,056423,735421,047418,414415,922413,122410,55192,11172,27460,101407,63735,66730,809-67,2392,811000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,684
Gross Profit-3,684-3,684
 
Operating Income (+$)
Gross Profit-3,684
Operating Expense-63,953
Operating Income-67,637-67,637
 
Operating Expense (+$)
Research Development47,931
Selling General Administrative19,706
Selling And Marketing Expenses3,684
Operating Expense63,95371,321
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-67,637
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-62,723-72,551
EBIT - interestExpense = -67,637
-62,723
-62,723
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-67,637-62,723
Earnings Before Interest and Taxes (EBITDA)-63,953
 
After tax Income (+$)
Income Before Tax-62,723
Tax Provision-0
Net Income From Continuing Ops-65,556-62,723
Net Income-62,723
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses67,637
Total Other Income/Expenses Net4,9140
 

Technical Analysis of Nextcure
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nextcure. The general trend of Nextcure is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nextcure's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NextCure  Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.57 < 2.66 < 2.66.

The bearish price targets are: 1.4 > 1.37 > 1.15.

Tweet this
NextCure  Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NextCure  Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NextCure  Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NextCure  Inc. The current macd is -0.03278555.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nextcure price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nextcure. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nextcure price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
NextCure  Inc Daily Moving Average Convergence/Divergence (MACD) ChartNextCure  Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NextCure  Inc. The current adx is 22.61.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nextcure shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
NextCure  Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NextCure  Inc. The current sar is 2.09308235.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NextCure  Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NextCure  Inc. The current rsi is 41.57. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
NextCure  Inc Daily Relative Strength Index (RSI) ChartNextCure  Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NextCure  Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nextcure price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NextCure  Inc Daily Stochastic Oscillator ChartNextCure  Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NextCure  Inc. The current cci is -111.22519024.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
NextCure  Inc Daily Commodity Channel Index (CCI) ChartNextCure  Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NextCure  Inc. The current cmo is -27.86057632.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NextCure  Inc Daily Chande Momentum Oscillator (CMO) ChartNextCure  Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NextCure  Inc. The current willr is -88.18181818.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
NextCure  Inc Daily Williams %R ChartNextCure  Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NextCure  Inc.

NextCure  Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NextCure  Inc. The current atr is 0.19848671.

NextCure  Inc Daily Average True Range (ATR) ChartNextCure  Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NextCure  Inc. The current obv is 1,657,460.

NextCure  Inc Daily On-Balance Volume (OBV) ChartNextCure  Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NextCure  Inc. The current mfi is 55.80.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
NextCure  Inc Daily Money Flow Index (MFI) ChartNextCure  Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NextCure  Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

NextCure  Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NextCure  Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.574
Ma 20Greater thanMa 501.959
Ma 50Greater thanMa 1001.711
Ma 100Greater thanMa 2001.456
OpenGreater thanClose1.580
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nextcure with someone you think should read this too:
  • Are you bullish or bearish on Nextcure? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nextcure? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NextCure  Inc

I send you an email if I find something interesting about NextCure  Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NextCure  Inc.

Receive notifications about NextCure  Inc in your mailbox!